AstraZeneca PLC

AstraZeneca said the FDA accepted its regulatory filing for the investigational enzyme replacement therapy efzimfotase alfa in patients aged two years and older with hypophosphatasia, or HPP, and granted the application priority review, shortening the review period by four months, with a final decision expected during the first half of 2027. The filing is supported by data from three phase III studies: MULBERRY met its primary endpoint in treatment-naive children aged two to less than 12 years old, showing a significant improvement in bone health, and CHESTNUT showed that patients switching from Strensiq could maintain the benefits of treatment, while HICKORY did not meet its primary endpoint in treatment-naive individuals aged 12 years and older, though AstraZeneca reported a numerical improvement, particularly in patients with pediatric-onset disease. The company said efzimfotase alfa was generally well-tolerated with an acceptable safety profile across the three studies. The commercial angle rests on Strensiq, the established HPP treatment AstraZeneca gained through its 2021 acquisition of Alexion, which was approved by the FDA in 2015 as the first bone-targeted enzyme replacement therapy for HPP and generated $1.05 billion in sales in the first half of 2026, up 41% year over year. Efzimfotase alfa is designed to require lower injection volumes and substantially less frequent dosing, once every two weeks, compared with Strensiq's three- or six-times-weekly regimen. Elsewhere in the space, BioMarin Pharmaceutical entered HPP through its acquisition of Alesta Therapeutics, completed earlier this month, paying $275 million upfront with up to $215 million in additional milestone payments for ALE1, an oral small-molecule therapy in a phase I/IIa study, while Recursion Pharmaceuticals is developing the oral ENPP1 inhibitor REC-102, formerly REV102, which remains in IND-enabling studies with a data-driven decision on a phase I study expected before the end of this year.

AstraZeneca and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy, with 14.3 months median progression free survival and a 37% risk reduction versus pembrolizumab plus chemotherapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in late-stage trials, with a 29% to 34% exacerbation reduction. Management has pointed to more than US$10b in potential peak risk adjusted revenue from new drugs, and investors will focus on US and EU COPD approval decisions ahead of the first quarter of 2027 Prescription Drug User Fee Act date. The article was produced by Simply Wall St.

AstraZeneca PLC released full results from two successful late-stage trials of tozorakimab, an experimental chronic obstructive pulmonary disease drug that reduced moderate and severe flare-ups by roughly 30% across a broad patient population. The two trials showed reductions in moderate-to-severe COPD exacerbations of 29% to 34%, with the highest-eosinophil subgroup seeing a 43% reduction, and benefits appearing regardless of eosinophil levels, smoking status, or disease severity. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027, and AstraZeneca forecasts more than $5 billion in peak annual sales, an estimate CEO Pascal Soriot said the drug's commercial potential could exceed. AstraZeneca believes tozorakimab could reach a broader group of COPD patients than existing biologics such as Regeneron and Sanofi's Dupixent and GSK's Nucala, which only target those with high eosinophil counts. The company's oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year, as AstraZeneca targets $80 billion in annual revenue by 2030, though the drug still needs FDA approval and faces patent-expiry pressure on established products including Farxiga and Brilinta.

London stocks closed higher on Thursday, September 17, with the FTSE 100 ending at 10,816.14 points, up 127.67 points, or 1.19%, hitting its highest level in more than a week. The gain came after the Bank of England voted 6 to 3 to keep interest rates at 3.75%, in line with market expectations, and announced it would suspend sales of UK government bonds for six months and halt long-dated bond sales altogether. The move followed a global bond selloff just days earlier that pushed the UK's 30-year borrowing cost to 5.96%, its highest since 1998. BoE Governor Andrew Bailey warned that prolonged conflict in the Middle East could make tighter monetary policy necessary. Data from LSEG showed investors had already priced in at least a 0.25% rate hike from the BoE this year. Rate-sensitive bank shares rose 1.6%, with HSBC and Standard Chartered leading the market with gains of 2% and 2.2% respectively. AstraZeneca rose about 2.4% after Chinese authorities said they would invest nearly 200 million yuan, or 29.81 million dollars, to upgrade its manufacturing base and supply chain in the city of Wuxi. Bytes Technology surged 12% after stronger-than-expected first-half results and an upgrade to its full-year gross profit growth forecast.

Onco360 has been selected by AstraZeneca as a national pharmacy partner for Etcamah, also known as camizestrant, the company announced. The therapy is indicated for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. Etcamah is an estrogen receptor antagonist that binds to the ligand-binding domain of ERα, antagonizing both wild-type and mutated ESR1 and inducing proteasome-dependent degradation of ERα without agonizing it. Its approval was based on the phase 3 SERENA-6 study, in which Etcamah plus a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% versus an aromatase inhibitor plus a CDK4/6 inhibitor, with median PFS of 16 months versus 9.2 months and a hazard ratio of 0.44. The most common adverse reactions, occurring in at least 20% of patients, included decreased neutrophils, leukocytes, hemoglobin, lymphocytes and platelets, along with visual disturbances and fatigue.

AstraZeneca secured a major access win for Enhertu in England after the NHS reversed an earlier cost-effectiveness rejection, Reuters reported Thursday. Roughly 1,000 women a year could now become eligible for Enhertu to treat HER2-low metastatic breast cancer. The drug carries a published British price of 1,455 per 100-milligram vial, but AstraZeneca, Daiichi Sankyo and NICE did not disclose the economics of the reimbursement agreement. Earlier clinical evidence showed the therapy extending survival by around six months for some patients, giving the NHS a meaningful clinical case to reconsider access. The decision could also help expand access in Wales and Northern Ireland, widening Enhertu's commercial reach across the U.K., though the confidential discount, treatment duration and patient persistence will ultimately determine how much of the expanded access flows through to AstraZeneca's bottom line.

The FDA granted accelerated approval to AstraZeneca's camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer, Bloomberg reported on September 5, 2026, despite an FDA advisory panel voting in April that the drug lacked patient benefit. The approval covers use alongside a CDK4/6 inhibitor for patients with an ESR1 gene mutation, based on a Phase III trial showing the combination cut the risk of disease progression or death by 56% compared with standard treatment. Median progression-free survival reached 16 months versus 9.2 months with standard treatment. Etcamah is already approved in more than 30 countries and is projected to make over $5 billion in peak annual sales. The accelerated approval requires AstraZeneca to complete confirmatory studies, and the Oncologic Drugs Advisory Committee voted 6-3 against the drug's risk-benefit profile in April, with several members questioning the trial design and whether the treatment would provide long-term benefit.

AstraZeneca has pledged to invest $15bn in China, deepening Western pharmaceutical ties with a country that has become a bona fide drug superpower even as Washington moves to sever them. The company's chief executive, Sir Pascal Soriot, announced the investment during Sir Keir Starmer's Beijing visit, building on existing manufacturing and research sites in Beijing, Shanghai, Wuxi, Taizhou and Qingdao; China is now AstraZeneca's second-largest market, accounting for roughly 12pc of global turnover, with around 17,000 employees and four advanced manufacturing sites. GSK has struck a series of partnerships with Chinese labs, including a $1.3bn pact with Hutchmed for the bulk of licensing rights to what it called first-in-class cancer treatments, and an alliance with Hengrui Pharma worth up to $12bn. Industry-wide licensing deals totalled $138bn last year, a nearly tenfold jump since 2021, according to PharmCube. The US Biosecure Act, signed into law in December, bars companies reliant on federal contracts from working with Chinese biotech firms tied to the military, and the proposed Biotech Investment National Security Act would subject licensing deals involving Chinese companies to national security reviews. China had 1,255 drugs at the research stage by 2024, a nearly eight-fold jump in less than a decade, against 1,441 in America and 400 in Europe.

AstraZeneca's TAGRISSO (osimertinib) demonstrated an unprecedented eight-year overall survival benefit in early-stage EGFR-mutated non-small cell lung cancer in the ADAURA Phase III trial, reducing the risk of death by 47% versus placebo in the primary population of Stages II-IIIA patients. In the overall trial population of Stages IB-IIIA, TAGRISSO reduced the risk of death by 48%, with an estimated 79% of TAGRISSO-treated patients alive at eight years versus 64% of those on placebo. The updated exploratory results, presented at the IASLC 2026 World Conference on Lung Cancer in Seoul and simultaneously published in the Journal of Thoracic Oncology, showed an estimated 74% of TAGRISSO-treated patients alive at eight years versus 58% on placebo in the primary population. Roy S. Herbst, principal investigator in the ADAURA Phase III trial, noted a 16 percentage point improvement in overall survival at eight years versus placebo, while Susan Galbraith, AstraZeneca's Executive Vice President of Oncology Haematology R&D, said the results reinforce TAGRISSO as the adjuvant standard of care and backbone therapy across stages of the disease. Separately, real-world evidence presented at the conference from a retrospective cohort study of US patients with early-stage EGFRm NSCLC showed that early discontinuation of TAGRISSO before completing the three-year treatment course more than doubled the risk of disease recurrence or death.

AstraZeneca's late-stage trial found that combining Tagrisso with Orpathys significantly extended progression-free survival compared with Tagrisso alone in previously untreated patients with EGFR-mutated advanced non-small cell lung cancer whose tumors expressed moderate to high levels of the MET protein. Lead principal investigator Yi-Long Wu said the observed clinical benefit could reshape initial treatment for this distinct patient population. AstraZeneca also reported encouraging overall-survival benefits as a secondary objective, though the company did not establish that the result was statistically significant. The combination's safety profile was consistent with the known profiles of Tagrisso and Orpathys, with no new safety findings, but detailed adverse-event results have not yet been presented. The results could support AstraZeneca's target of $80 billion in total annual sales by 2030, with cancer medicines contributing nearly half of company sales and Tagrisso among its leading products; Orpathys is being developed with Hutchmed. A successful late-stage study does not by itself establish regulatory approval or commercial adoption, and much depends on the companies' application plans, regulatory timelines, and expected sales.

Amgen and AstraZeneca announced positive results from a phase III study of Imdelltra, or tarlatamab, in combination with AstraZeneca's Imfinzi, or durvalumab, in certain patients with extensive-stage small-cell lung cancer. The trial, called DeLLphi-305, tested the combination against Imfinzi alone as a first-line maintenance treatment for patients whose cancer had not progressed after induction with Imfinzi plus platinum chemotherapy and etoposide. The study met its primary endpoint of overall survival and a key secondary endpoint of progression-free survival, though neither company provided numerical data and both said no new safety concerns were identified. DeLLphi-305 is sponsored by Amgen, with partial funding and Imfinzi supplied by AstraZeneca. AstraZeneca estimates that roughly 195,000 people globally will be treated for extensive-stage small-cell lung cancer in 2026, and the companies say small-cell lung cancer accounts for about 15% of lung cancers, with about two-thirds of those patients diagnosed with the extensive-stage form. If approved, the Imfinzi-Imdelltra combination would enter a first-line maintenance market where the FDA in October 2025 approved Jazz Pharmaceuticals' Zepzelca, or lurbinectedin, with Roche's Tecentriq, or atezolizumab, based on the IMforte study, which showed a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death versus Tecentriq alone. Imdelltra, a bispecific T-cell engager approved in 2024 for second-line extensive-stage small-cell lung cancer, posted global sales of $546 million in the first half of 2026, up from $215 million a year earlier, while Imfinzi's first-half 2026 revenues rose 31% year over year to $3.55 billion.

Deutsche Bank kept a 'sell' rating and 11,500 pence target price on AstraZeneca even as it praised detailed OBERON and TITANIA results for tozorakimab in chronic obstructive pulmonary disease presented at the ERS conference. The shares traded at 11,634p, broadly flat. Analyst Emmanuel Papadakis said the data impressed despite minor caveats and supported the drug's commercial prospects, following headline results in March and AstraZeneca's decision to raise peak sales guidance above $5 billion alongside second-quarter results. Consensus sales forecasts stand around $4 billion for 2030 and beyond, leaving room for modest upward revisions, the note said. Papadakis also highlighted positive headline findings from a niche Imfinzi study in small cell lung cancer maintenance treatment, and the broker judged the developments a minor positive for AstraZeneca. The next financial catalyst is whether consensus sales estimates move higher as analysts absorb the detailed COPD findings and reassess tozorakimab's peak revenue potential.

AstraZeneca's shares fell about 1.3% to $158 on Wednesday, even after its experimental COPD treatment, tozorakimab, met primary endpoints in two Phase 3 trials. The drug reduced moderate or severe flare-ups by 29% and 34% among former smokers in the OBERON and TITANIA studies, respectively, with reductions of roughly 30% and 29% across broader patient groups. The trials involved 2,306 patients, and no new safety signals were identified. The FDA has granted priority review, with a decision expected in the first quarter of 2027. AstraZeneca reported first-half revenue of $30.7 billion and core operating profit of $10.5 billion, implying a 34.2% margin. At $158, the stock trades 12.48% below its GF Value estimate of $180.52, suggesting potential upside if the drug gains approval and commercial success.

Amgen's Imdelltra sales surged 115% to $288 million in the second quarter, as the drug combined with AstraZeneca's Imfinzi met every major goal in a late-stage lung-cancer trial. The 563-patient DeLLphi-305 study showed the combination extended overall survival and progression-free survival with better response rates than Imfinzi alone as maintenance therapy for extensive-stage small-cell lung cancer. Amgen reported no new safety signal, but the crucial efficacy numbers remain undisclosed until a future medical meeting. The quarterly sales represent roughly 2.9% of Amgen's $10.1 billion total revenue, pointing to an annualized pace above $1.15 billion, more than double the drug's 2025 revenue. Shares traded at $391.65, 7.05% above the GF Value estimate of $365.84, with the muted reaction suggesting investors await survival data to gauge the drug's full commercial potential.

AstraZeneca announced that full results from the Phase III OBERON and TITANIA trials show tozorakimab is the first biologic to achieve statistically significant and highly clinically meaningful reductions in moderate and severe COPD exacerbations across a broad patient population, including former and current smokers and all blood eosinophil counts. Compared with placebo, tozorakimab 300mg every four weeks reduced exacerbations by 29% in former smokers in OBERON and 34% in TITANIA, and by 30% and 29% respectively in the overall population. A pooled analysis found reductions of 23% in patients with baseline eosinophils below 150, 34% in those at or above 150, and 43% in those at or above 300. The results were published in the New England Journal of Medicine and presented at the European Respiratory Society Congress 2026, and the US FDA has accepted the Biologics License Application for Priority Review with a PDUFA date anticipated in the first quarter of 2027.

AstraZeneca's ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor has been approved in the US for the first-line treatment of adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy. The accelerated approval is based on results from the pivotal SERENA-6 Phase III trial, which showed that the combination reduced the risk of disease progression or death by 56% compared with standard-of-care treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, with median progression-free survival of 16.0 months versus 9.2 months. The FDA also concurrently approved a companion diagnostic test to detect emerging ESR1 resistance mutations in circulating tumor DNA. This approval marks AstraZeneca's tenth FDA approval this year and its fourth in breast cancer, and ETCAMAH is the first and only medicine of its type in the first-line setting. ETCAMAH is also approved in more than 30 countries, including the EU, Japan, Canada, and the UK.

C4X Discovery Holdings announced it will receive a $13 million milestone payment from AstraZeneca, triggered by the entry of its oral NRF2 activator programme into the clinic. Under the licensing agreement announced in November 2022, C4XD is eligible for up to $400 million in preclinical, clinical development, and commercial milestones, plus tiered mid-single digit royalties on future sales. AstraZeneca is advancing AZD4916, an oral NRF2 activator, in a Phase I study in healthy volunteers for inflammatory and respiratory diseases. C4XD's CSO Nick Ray and CEO Emma Blaney expressed optimism about the programme's progress and the company's other pipeline assets, including α4β7 and PAD4 programmes.

AstraZeneca announced positive results from the phase III SANOVO study, showing that Tagrisso plus Orpathys significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced or metastatic non-small cell lung cancer and MET overexpression. The study, conducted with partner HUTCHMED, also showed encouraging overall survival improvements, though follow-up continues. The combination is already approved in China for later-line treatment, and these results could support its use in the first-line setting. Year to date, AstraZeneca's shares have fallen 11.7%, compared with the industry's 8.7% growth.

AstraZeneca has received European Union approval for a first-line Enhertu plus pertuzumab combination for HER2-positive breast cancer, marking the first new first-line regimen in over a decade, and has completed a global license agreement for lung cancer drug ZEGFROVY, securing worldwide rights to a next-generation EGFR inhibitor with breakthrough designations. These oncology milestones expand AstraZeneca's approved treatment options in breast cancer and reinforce its position in lung cancer. The company, a £185.7 billion biopharmaceutical firm, is using its antibody drug conjugate and targeted therapy platforms to deepen its presence in these large global markets. The news supports the narrative that new oncology medicines could collectively add more than $10 billion in peak risk-adjusted revenue, though it also highlights reliance on partnered assets and the need to earn returns on sizeable outlays such as the $600 million upfront ZEGFROVY payment and future milestones. Investors will watch for how quickly Enhertu uptake in the EU shows up in reported sales and whether AstraZeneca provides timelines for ZEGFROVY development.

DelveInsight reports that the PCSK9 inhibitors market is entering a high-growth phase, driven by the FDA approval of Merck's LIPFENDRA, the first oral PCSK9 inhibitor, and the emergence of next-generation oral drugs from AstraZeneca, Aqur Biosciences, and others. The market was valued at USD 3 billion in the 7MM in 2025, with the United States holding the largest share. Key pipeline candidates include Recaticimab, VERVE 102, AZD0780, AQR-008, and LIB003, with LEQVIO expected to generate the highest revenue by 2036. The report covers indications such as dyslipidemia, hypercholesterolemia, ASCVD, and others, and highlights that oral and gene therapies offer significant potential to reduce patient burden and improve adherence.

AstraZeneca has completed its exclusive license agreement with Dizal Pharmaceutical for ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for lung cancer, acquiring worldwide rights to develop and commercialize the drug. The deal includes an upfront payment of $600 million to Dizal, with additional payments of up to $900 million tied to development, regulatory, and sales milestones, plus tiered royalties on global sales. ZEGFROVY is already approved in the US and China for second-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, and AstraZeneca plans to launch it in the US in the fourth quarter of 2026. A supplemental New Drug Application for first-line use has been accepted by the US FDA, supported by positive Phase III trial results, and a similar submission is under review in China. The transaction does not affect AstraZeneca's 2026 financial guidance.

The European Commission has approved Enhertu in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer, marking the first new regimen in over a decade for this indication. The approval is based on the DESTINY-Breast09 phase 3 trial, which showed that the combination reduced the risk of disease progression or death by 44% versus THP, with a median progression-free survival of 40.7 months compared to 26.9 months. This is the second approval for Enhertu in the EU in two months, following a recent tumor-agnostic approval. Daiichi Sankyo and AstraZeneca jointly developed the drug, and AstraZeneca will pay Daiichi Sankyo a $100 million milestone payment following this approval. The combination is now approved in more than 40 countries worldwide for this indication.

The global cytotoxic drugs market is projected to grow from $16.21 billion in 2026 to $21.06 billion by 2031, at a compound annual growth rate of 5.37%, according to a new report from ResearchAndMarkets.com. Rising cancer incidence, earlier diagnosis, expanded reimbursement, and growing demand in emerging economies are driving the market. In 2025, the market was valued at $15.38 billion, with parenteral drugs holding a 68.87% share, while oral drugs are expected to grow faster at an 8.79% CAGR. Alkylating agents led with a 30.10% share in 2025, but antimetabolites are forecast to grow fastest at 7.02% CAGR. North America accounted for 42.15% of revenue in 2025, while Asia-Pacific is projected to grow at 10.07% CAGR, supported by China's approval of 228 drugs in 2024, 37% of which were antineoplastics. Key players include Pfizer, Roche, Novartis, AstraZeneca, and Sanofi.

AstraZeneca has reported positive high-level results from several late-stage oncology and immunology trials, including TEZSPIRE in eosinophilic esophagitis, which met key clinical goals. The DESTINY-Lung04 and SAFFRON trials in non-small cell lung cancer also showed encouraging progress. As part of pipeline prioritisation, the company has initiated a pivotal Phase 3 trial of Datroway in high-risk muscle-invasive urothelial cancer and terminated an underperforming lung cancer study. These developments support AstraZeneca's strategy to expand its treatment portfolio in serious diseases, with management estimating that new medicines could generate over $10 billion in peak risk-adjusted revenue. The company, with a market cap of £187.9 billion, is focusing on antibody-drug conjugates and complex immunology biologics to counter patent and pricing pressures on existing blockbusters.

AstraZeneca's stock remained 14% below its pre-Wainua failure level despite positive Phase 3 data for Tezspire, trading at $164.75 on Thursday. The CROSSING study showed both Tezspire doses significantly reduced tissue inflammation and eased swallowing problems in patients with eosinophilic esophagitis, with effects lasting through week 52 and a safety profile consistent with approved uses. Tezspire generated $1.13 billion of AstraZeneca's 2025 sales and $1.48 billion for partner Amgen, yet it represents only about 1.4% of AstraZeneca's $80 billion revenue target for 2030. The shares sit 9.25% below their $181.55 GF Value estimate, but investors seek broader pipeline proof rather than a single clinical win.

AstraZeneca and Amgen announced positive high-level results from the Phase III CROSSING trial, showing that TEZSPIRE (tezepelumab-ekko) achieved statistically significant and clinically meaningful improvements across both co-primary and all key secondary endpoints in patients with eosinophilic esophagitis (EoE) at week 24, with effects sustained through week 52 in both doses tested. The co-primary endpoints were histologic remission and the frequency and severity of dysphagia compared to placebo, and the safety profile was consistent with approved indications. EoE is a chronic inflammatory disorder affecting over 470,000 people in the US, and nearly half of patients do not achieve adequate control with current first-line treatments. The results mark the third epithelial-driven inflammatory disease where TEZSPIRE has shown efficacy, and full results will be shared with regulatory authorities and at an upcoming medical meeting.

Daiichi Sankyo and AstraZeneca have dosed the first patient in the TROPION-Urothelial04 phase 3 trial, evaluating Datroway plus rilvegostomig or Datroway monotherapy versus current standard of care as adjuvant treatment for patients with high-risk muscle invasive urothelial cancer. The trial will enroll approximately 915 patients across Asia, Europe, North America, Oceania, and South America, with disease-free survival as the primary endpoint. This is the second pivotal trial for Datroway in urothelial cancer, following encouraging results from earlier studies. Muscle invasive urothelial cancer represents about 30% of all urothelial cancer cases, and there are currently no TROP2-directed medicines approved for this disease.

AstraZeneca is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical, with up to $900 million in additional milestone payments bringing the deal's potential value to $1.5 billion. Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months compared with 7.5 months for chemotherapy. Dizal reported approximately $85 million or 576 million yuan in Zegfrovy revenue during 2025, an increase of roughly 85% from the previous year. AstraZeneca will take responsibility for the treatment's global development and commercialisation, and the deal supports its goal of reaching $80 billion in annual revenue by 2030.

Dizal Pharmaceutical released its 2026 interim report. First-half operating revenue reached 523 million yuan, up 47.24% year on year, while net profit attributable to the parent company was negative 210 million yuan, narrowing the loss by 167 million yuan compared with the same period last year. Both core products, Sunvozertinib and Golidocitinib, have been included in the national medical insurance drug list, driving all revenue from the domestic market. Gross margin reached 96.00%, and net margin improved to negative 40.77% from negative 106.29% a year earlier. Selling expenses fell 10.16% year on year to 241 million yuan. Research and development investment was 402 million yuan, down 1.53% year on year, and R&D expenses as a share of revenue dropped to 76.92% from 115.00%. In July 2026, the company signed a license agreement with AstraZeneca, granting exclusive global development and commercialization rights for Sunvozertinib. It expects to receive an upfront payment of 600 million US dollars, up to 400 million US dollars in clinical development milestone payments, up to 500 million US dollars in sales milestone payments, and royalties. The transaction is expected to close in the second half of 2026.

Healthcare ETFs are hitting one-year highs as the sector benefits from improving earnings visibility, attractive relative valuations, and a rotation out of overcrowded AI and tech trades into defensive growth. State Street Health Care Select Sector SPDR ETF XLV has surged 6.6% over the past month compared with 3.4% gains for State Street SPDR S&P 500 ETF Trust SPY. S&P 500 healthcare companies are expected to deliver double-digit earnings growth from Q4 2026 through 2027, and the sector is expected to log a 21.2% increase in earnings on 2.2% higher revenues, according to Zacks Sector and Market Earnings Trends issued on Aug. 12, 2026. M&A value in the sector has touched nearly $284 billion this year, approaching 2025's total of $306 billion, and hedge fund bets in favor of healthcare stocks recently neared a five-year high, per a Goldman Sachs note. The FDA has accelerated its approval process, with the annual number of new drug approvals in 2025 reaching its highest level since 2020.